Phase I Trial of Vorinostat (MK-0683, SAHA) in Combination With Decitabine in Patients With AML or MDS (MK-0683-055 EXT1)

NCT00479232 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

71

Enrollment

INDUSTRY

Sponsor class

Conditions

Leukemia, Myelocytic, Acute Myelodysplastic Syndromes
Myelodysplastic Syndromes

Interventions

DRUG: vorinostat
DRUG: decitabine

Sponsor

Merck Sharp & Dohme LLC